Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KURA 
Kura Oncology Inc (KURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: KURA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $27
1 Year Target Price $27
| 10 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26.86% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 710.87M USD | Price to earnings Ratio - | 1Y Target Price 27 |
Price to earnings Ratio - | 1Y Target Price 27 | ||
Volume (30-day avg) 15 | Beta 0.19 | 52 Weeks Range 5.41 - 21.40 | Updated Date 09/15/2025 |
52 Weeks Range 5.41 - 21.40 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -236.76% | Operating Margin (TTM) -475.31% |
Management Effectiveness
Return on Assets (TTM) -22.93% | Return on Equity (TTM) -51.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 99613945 | Price to Sales(TTM) 8.54 |
Enterprise Value 99613945 | Price to Sales(TTM) 8.54 | ||
Enterprise Value to Revenue 1.2 | Enterprise Value to EBITDA -2.48 | Shares Outstanding 86797200 | Shares Floating 63935674 |
Shares Outstanding 86797200 | Shares Floating 63935674 | ||
Percent Insiders 1.2 | Percent Institutions 95.88 |
Upturn AI SWOT
Kura Oncology Inc
Company Overview
History and Background
Kura Oncology Inc. was founded in 2014 and is headquartered in San Diego, California. It is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for the treatment of cancer. The company is primarily focused on hematologic malignancies and solid tumors.
Core Business Areas
- Drug Development: Focuses on developing novel therapies that target specific cancer-causing pathways, including those driven by dysregulation of the Ras signaling pathway and epigenetic modifications.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in patients with various types of cancer.
- Commercialization: Plans to commercialize its products upon regulatory approval, targeting specific patient populations with unmet medical needs.
Leadership and Structure
Troy Wilson, Ph.D., J.D., is the President and Chief Executive Officer. The company has a board of directors and a management team overseeing research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Tipifarnib (Zipalertu2122): Tipifarnib is an orally bioavailable inhibitor of farnesyltransferase, a protein involved in cancer cell growth. It is approved for HRAS-mutant HGSOC (High-Grade Serous Ovarian Cancer) following prior platinum-based chemotherapy. It is now commercialized in the US. Competing therapies include standard chemotherapy regimens and other targeted therapies. No direct market share available.
- KO-2806: KO-2806 is a next-generation ERK inhibitor in preclinical development targeting the MAPK pathway, which is often dysregulated in cancer. It is a preclinical compound, so no market share or revenue is currently attributable. Competitors in this space are other companies developing ERK inhibitors.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. The oncology segment is a large and growing market with high unmet medical needs. Precision medicine approaches, such as those pursued by Kura Oncology, are gaining prominence.
Positioning
Kura Oncology is positioned as a precision medicine company focusing on developing targeted therapies for specific cancer subtypes. Its competitive advantage lies in its pipeline of novel drug candidates and its focus on well-defined patient populations with unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for oncology therapeutics is estimated to be in the hundreds of billions of dollars globally. Kura Oncology is positioned to capture a portion of this market through its targeted therapies, focusing on specific cancer subtypes with high unmet needs. TAM for HRAS-mutant HGSOC is more precisely defined, and Kura will likely have more success commercializing to this focused market.
Upturn SWOT Analysis
Strengths
- Precision medicine approach
- Novel drug candidates targeting specific cancer pathways
- Experienced management team
- Focus on unmet medical needs
- Tipifarnib FDA approval
Weaknesses
- Limited commercial infrastructure
- Reliance on clinical trial success
- High cash burn rate
- Dependence on key personnel
- Single approved drug driving revenue
Opportunities
- Expanding indications for Tipifarnib
- Advancing KO-2806 through clinical development
- Strategic partnerships and collaborations
- Acquisition or in-licensing of complementary technologies
- Positive clinical trial data releases
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Patent expirations
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- GILD
- MRTX
- LLY
Competitive Landscape
Kura Oncology faces competition from established pharmaceutical companies with larger resources and broader pipelines. Kura's advantage lies in its specialized focus and innovative approach to precision medicine.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by advancements in the clinical pipeline and successful fundraising activities.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates, particularly KO-2806. Analyst estimates vary but generally reflect optimism regarding the company's potential.
Recent Initiatives: Recent initiatives include progressing Tipifarnib, commercializing Zipalert, and advancing clinical trials for KO-2806.
Summary
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for cancer. It is considered weak due to its relatively small size and reliance on clinical trial successes. What's working well is its focus on developing targeted therapies and advancing its clinical pipeline. Kura Oncology needs to watch out for clinical trial failures and competition from larger pharmaceutical companies and also the financial risks around burning through their capital to advance their clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Investor Presentations, Analyst Reports, Press Releases
- Yahoo Finance
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kura Oncology Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-09-22 | Chairman, CEO & President Dr. Troy Edward Wilson J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 192 | Website https://kuraoncology.com |
Full time employees 192 | Website https://kuraoncology.com | ||
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.